Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Federal Trade Commission
Harvard Business School
Chubb
Merck
Johnson and Johnson
Fuji
Cerilliant
Teva

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,475,780

« Back to Dashboard

Summary for Patent: 8,475,780
Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Klaerner; Gerrit (Los Gatos, CA), Buysse; Jerry M. (Los Altos, CA), Liu; Mingjun (Campbell, CA)
Assignee: Relypsa, Inc. (Redwood City, CA)
Application Number:13/015,134
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,475,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERKALEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,475,780

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,778,324 Ion binding polymers and uses thereof ➤ Sign Up
7,429,394 Ion binding compositions ➤ Sign Up
7,776,319 Methods and compositions for treatment of ion imbalances ➤ Sign Up
8,282,913 Ion binding polymers and uses thereof ➤ Sign Up
8,445,014 Ion binding compositions ➤ Sign Up
7,854,924 Methods and compositions for treatment of ion imbalances ➤ Sign Up
8,192,758 Ion binding compositions ➤ Sign Up
8,282,960 Ion binding compositions ➤ Sign Up
8,216,560 Ion binding polymers and uses thereof ➤ Sign Up
8,147,873 Methods and compositions for treatment of ion imbalances ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,475,780

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom 2430624 ➤ Sign Up
Canada 2806465 ➤ Sign Up
Canada 2829943 ➤ Sign Up
China 1980639 ➤ Sign Up
China 1980645 ➤ Sign Up
China 101001614 ➤ Sign Up
China 102133196 ➤ Sign Up
China 103251571 ➤ Sign Up
Germany 112005000708 ➤ Sign Up
Germany 112005000725 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Moodys
Farmers Insurance
Express Scripts
QuintilesIMS
Covington
Argus Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot